Drug Profile
DFP 11207
Alternative Names: DFP-11207Latest Information Update: 06 Jul 2023
Price :
$50
*
At a glance
- Originator Delta-Fly Pharma
- Class Antineoplastics; Benzoates; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Propionates; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Thymidylate synthase expression inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Solid tumours
Most Recent Events
- 06 Jul 2023 Delta-Fly Pharma plans a phase II trial for Solid tumours in USA and Japan in 2025 (Delta-Fly Pharma pipeline, July 2023)
- 28 Jul 2021 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
- 20 Jan 2020 Chemical structure information added